The best therapeutic option for oral treatment of secondary anaemia in chronic kidney disease: role of Ferric Sodium EDTA, in association with Vitamin C, Folic acid, Copper gluconate, Zinc Gluconate and Selenomethionine

Lucia Laura Bilo,Luca Di Lullo,Adriana Romano,Nicola Marchitto,Gianfranco Raimondi,Annalisa Curcio,Michele Pironti

doi:10.15761/nrd.1000184

Abstract

The best therapeutic option for oral treatment of secondary anaemia in chronic kidney disease: role of Ferric Sodium EDTA, in association with Vitamin C, Folic acid, Copper gluconate, Zinc Gluconate and Selenomethionine

Highlights

Iron deficiency anaemia (IDA) represents a serious co-morbidity in patients with chronic kidney disease (CKD), that impacts patient’s quality of life, physical and cognitive functions
The aim of this study is to evaluate the effect of Ferric Sodium EDTA, in combination with vitamin C, folic acid, copper gluconate, zinc gluconate and selenomethionine (Ferachel forte®) treatment in nondialysis-dependent chronic kidney disease (NDD-CKD) elderly patients with secondary anaemia not responders to ferrous sulphate therapy, in comparison with an oral liposomal iron formulation
After evaluation of blood parameters at T1 patients were randomized to treatment with Ferric Sodium EDTA in combination with vitamin C, folic acid, copper gluconate, zinc gluconate and selenomethionine (Ferachel Forte®) 1 tab/day, containing 30 mg of ferric ion (Group 1; N=15), or with Ferric liposomal formulation, containing 30 mg of ferric ion (Group 2; N=15), for 6 months (T2, Figure 1)

Summary

Introduction

Iron deficiency anaemia (IDA) represents a serious co-morbidity in patients with chronic kidney disease (CKD), that impacts patient’s quality of life, physical and cognitive functions. There is a correlation between anaemia worsening and kidney function decline, showing an increased risk of progression to end-stage kidney disease (ESKD) in anaemic patients. Iron deficiency anaemia (IDA) represents a serious co-morbidity in patients with chronic kidney disease (CKD), that impacts patient’s quality of life, physical and cognitive functions and is associated with an increased risk of adverse outcomes, including cardiovascular disease (CVD), cardiovascular hospitalization and mortality for any cause [1,2].

Objectives

Methods

Results